Brief: Hyloris Pharmaceuticals Broadens Pipeline With Nasal Product Candidate For Idiopathic Rhinitis
22/11/2022 17:05
Nov 22 (Reuters) - Hyloris Pharmaceuticals SA HYL.BR :
* HYLORIS PHARMACEUTICALS BROADENS PIPELINE WITH A NASAL
PRODUCT
CANDIDATE FOR IDIOPATHIC RHINITIS
* ADDITION OF THIS NEW VALUE-ADDED PRODUCT CANDIDATE BRINGS
HYLORIS TOWARD ITS GOAL OF 30 ASSETS BEFORE 2025
* HYLORIS TARGETS A CONDITION THAT AFFECTS UP TO 7% OF
GLOBAL
ADULT POPULATION WITHOUT ANY SATISFACTORY TREATMENT CURRENTLY
AVAILABLE
Source text for Eikon: ID:nGNE4g0lFF
Further company coverage: HYL.BR
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on Hyloris Pharmaceuticals SA
See all newsEurope Research Roundup: Akzo Nobel, MTU Aero Engines, Symrise
Brief: Hyloris Pharmaceuticals Says It Obtains Exclusive License Rights In Europe & Turkey From Arbormed For Its Wilson's Disease Therapy
Brief: Hyloris Announces Partnership With Rosemont Pharmaceuticals For Atomoxetine Oral Solution In The U.S.
Brief: Hyloris Announces Positive Study Results For Dofetilide IV
Brief: Hyloris Pharmaceuticals SA Says HY 2024 Revenues (Royalties And Milestones) Increased To EUR 4,2 Million